{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T12:01:59Z","timestamp":1724328119627},"reference-count":13,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vaccine.2014.08.044","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T18:45:39Z","timestamp":1409165139000},"page":"5549-5551","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The costs associated with the public health management of a cluster of meningococcal infection in England"],"prefix":"10.1016","volume":"32","author":[{"given":"Dominique","family":"Letouze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiqing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart C.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"May (24)","key":"10.1016\/j.vaccine.2014.08.044_bib0005","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.044_bib0010","unstructured":"Letter from the Chief Medical Officer (1999)4: Start of the new meningococcal C conjugate vaccine immunisation programme, Available at: \u3008http:\/\/webarchive.nationalarchives.gov.uk\/+\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Lettersandcirculars\/Professionalletters\/Chiefmedicalofficerletters\/DH_4004088\u3009. Accessed: 4 December 2012."},{"key":"10.1016\/j.vaccine.2014.08.044_bib0015","series-title":"First national report on the current status of the universal vaccine programmes from the Centre for Infections","article-title":"Protecting the health of England's children: the benefit of vaccines","author":"Health Protection Agency Centre for Infections","year":"2005"},{"issue":"3","key":"10.1016\/j.vaccine.2014.08.044_bib0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/adc.2003.031369","article-title":"Clusters of meningococcal disease in school and preshool settings in England and Wales: what is the risk?","volume":"89","author":"Davison","year":"2004","journal-title":"Arch Dis Child"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2014.08.044_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","article-title":"Counting the cost of meningococcal disease","volume":"15","author":"Wright","year":"2013","journal-title":"Pediatric Drugs"},{"issue":"23","key":"10.1016\/j.vaccine.2014.08.044_bib0030","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.044_bib0035","unstructured":"European Medicines Agency \u2018Summary of opinion (initial authorisation): Bexsero\u2019 15 November 2012 EMA\/CHMP\/669278\/2012 Committee for Medicinal Products for Human Use (CHMP) Available at: \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002333\/WC500134836.pdf\u3009 (accessed on: 28 January 2014)."},{"key":"10.1016\/j.vaccine.2014.08.044_bib0040","unstructured":"JCVI interim position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK July 2013 Available at: \u3008https:\/\/www.gov.uk\/government\/publications\/jcvi-interim-position-statement-on-the-use-of-bexsero-meningococcal-b-vaccine-in-the-uk\u3009 (accessed August, 2013; accessed on: 28 January 2014)."},{"key":"10.1016\/j.vaccine.2014.08.044_bib0045","unstructured":"JCVI position statement on the use of Bexsero meningococcal B vaccine in the UK, March 2014 \u3008https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf\u3009."},{"key":"10.1016\/j.vaccine.2014.08.044_bib0050","unstructured":"Health Protection Agency Meningococcus and Haemophilus Forum. Guidance for public health management of meningococcal disease in the UK. Updated March 2012. Available at: http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1194947389261 Accessed 28 January 2014."},{"key":"10.1016\/j.vaccine.2014.08.044_bib0055","unstructured":"Agenda for Change (all NHS and HPA staff). Available at: \u3008http:\/\/www.nhscareers.nhs.uk\/working-in-the-nhs\/pay-and-benefits\/agenda-for-change-pay-rates\/\u3009 (correct for 2012) Accessed: 12 June 2012."},{"key":"10.1016\/j.vaccine.2014.08.044_bib0060","unstructured":"Wrightington, Wigan and Leigh pay and grading structures of senior staff, Available at: \u3008www.wwl.nhs.uk\u3009 (correct for 2012) (accessed: 12 June 2012)."},{"key":"10.1016\/j.vaccine.2014.08.044_bib0065","unstructured":"\u3008www.bnf.org\u3009 (accessed: 12 June 2012)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T07:56:06Z","timestamp":1538294166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14011670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":13,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0264410X14011670"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The costs associated with the public health management of a cluster of meningococcal infection in England","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}